Niki BioSolutions, Inc.
NIKIHealthcareNASDAQBiotechnology · Last scanned Oct 22, 2026
Scan Results
Daily timeframeNiki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to. With a market capitalization of $6.2M, it sits in micro-cap territory. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in a Phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa.
Market Cap
$6.2M
Beta
-1.00
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-2.90
EPS (Fwd)
—
ROE
-17.1%
ROA
-10.0%
Cash
$1.8M
Total Debt
$3.5M
Free CF
-$1.7M
52W Change
-86.7%
Annual Financials
Cash vs Debt
Where NIKI stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, NIKI finished 73.50% below its 150-day moving average ($7.85) and 74.32% below its 200-day moving average ($8.10). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NIKI overbought or oversold?
At the October 20, 2026 close, NIKI's RSI(14) was 16.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $1.8M in cash, though total debt stands at $3.5M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$1.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -17.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $1.3M (2022) to $0 (2025), a 100% decline worth watching.
With a beta below 0.7, Niki BioSolutions, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing NIKI.